Proligestone is a third generation synthetic steroid of progesterone with potentially less side effects (Romagnoli & Concannon, 2003) . The posology recommended by the manufacturer varies from 10 to 33 mg/kg body weight in a single subcutaneous injection. To prevent oestrus, proligestone should be administered in anestrus or as soon as the onset of proestrus is observed. Treatment in late proestrus or oestrus is more likely to be ineffective. Efficacy can be measured by the decrease of clinical signs of proestrus like reduction of bloody vaginal secretion and attractiveness to male dogs.
If the treatment is done in proestrus, contact to male dogs should be forbidden, since breeding and pregnancy are at risk. Oestrus is prevented on average for 5-6 months (Concannon, 2004) . For permanent postponement of heat, a second injection of proligestone should be done three to 4 months after the first one and then repeated every 5 months. Not all bitches respond to proligestone treatment. Anestrus is observed, usually, from 3 to 9 months after treatment (Romagnoli & Concannon, 2003) , and around 3% of bitches may not return to oestrus after treatment for permanent postponement of heat according to the manufacturer, limiting this use in animals with reproductive potential. Fertility seems not to be adversely affected after proligestone is withdrawn (Romagnoli & Concannon, 2003) .
The mechanism of the contraceptive activity of progestins is still unclear, although it is commonly described that it mimics the luteal phase due to its progesterone-like effects and affinity to progesterone receptor (PR). The direct effect of progestins on the gonadotropin levels in bitches remains controversial. No influence of progestin was found by McCann et al. (1987) and Colon, Kimball, Hansen, and Concannon (1993) , and only scarce action on the hypothalamuspituitary-ovarian axis is described by Beijerink, Buijtels, Okkens, Kooistra, and Dieleman (2007) . Nevertheless, it is well-documented that under progestin treatment, the ovarian function (follicular phase, ovulation and luteal phase) is blocked in the majority of bitches. Most likely, progestins modulate rather than decrease the pulsatile secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) leading to suppression of follicle development and anestrus (Romagnoli & Concannon, 2003) . Furthermore, a direct inhibitory effect of MPA at the ovarian level resulting in suppression of ovarian secretion of oestradiol or inhibin has been postulated (Mann, Campbell, McNeilly, & Baird, 1992; Shupnik, 1996) . In addition, the pituitary FSH response to GnRH stimulation decreased, suggesting that MPA treatment attenuated pituitary FSH sensitivity to endogenous GnRH (Beijerink et al., 2007) . If used prior to or in early proestrus, progestins inhibit the LH surge by, most likely, direct action on the hypothalamic GnRH secretion and on pituitary responses to oestrogens and consequently prevent ovulation. However, as suggested by Romagnoli and Concannon (2003) , if the administration is done around the endogenous peak of oestradiol, the effect might be stimulatory to the pre-ovulatory LH surge and ovulation.
Between progestins, differences in the short-life and affinity to progesterone receptor must be considered. MPA is slowly metabolized by the liver while MA is a shorter acting drug. Proligestone, should in principle, have a lower affinity to PR and glucocorticoid receptor (GR), compared to MPA. Nevertheless, in vitro, both progestins show a similar binding specificity to PR and GR (Selman, Wolfswinkel, & Mol, 1996) . Anecdotal reports suggest that proligestone has similar potential for undesirable reproductive and metabolic side effects (Concannon, 2004) .
There are many side effects associated with the use of progestins. The spectrum of side effects is related to the product, the dose, the frequency of use and the stage of the oestrous cycle in which the drug is administered. Side effects included weight gain, lethargy, behavioural changes, increasing in the prevalence of cystic endometrial hyperplasia (CEH)-pyometra complex (De Cock, Ducatelle, Tilmant, & De Schepper, 2002; Kim & Kim, 2005; Sokolowski & Zimbelman, 1974) , mammary gland enlargement and neoplasia (Stovring, Moe, & Glattre, 1997) , the diabetogenic effect (Selman, Mol, Rutteman, & Rijnberk, 1994a; Selman et al., 1997) , acromegaly, adrenocortical suppression (Selman, Mol, Rutteman, & Rijnberk, 1994b) and local skin changes at the injection site. Due to the side effects, progestins are not recommended for bitches with the previous history of uterine disease, diabetes mellitus, mammary tumours or liver disease. Despite the proven potential of side effects, progestins can be used safely provided a correct selection of the treated animal. Treatment should be done during anestrus in young and healthy bitches, without uterine, mammary or endocrine diseases, with the right dosage for the proper length of time (Romagnoli & Lopate, 2017) . Blind evaluation of the uterine modifications of MPA treated and old multiparous bitches revealed no quantitative differences in morphological changes in both groups (Salinas, Miglino, & del Sol, 2017) .
In general, the progestins should be used exclusively under veterinary supervision and repeated treatments in breeding bitches must be carefully considered. A maximum of two successive oestrous cycles should be suppressed, and then, the bitch should have a normal spontaneous oestrous cycle. Ideally, progestins should be given in advanced anestrus or a few weeks before the expected proestrus. Administration during early proestrus (3 days) can potentially prevent ovulation and the normal progression of oestrus. The use during proestrus needs to be carefully surveyed since the bitch could be bred and become pregnant, and in this case, the treatment should be discontinued and also there is an increased risk of uterine diseases. As has been described for a long time (Brodey & Fidler, 1966; Nelson & Kelly, 1976) , treatment with progestins can lead to uterine diseases, especially CEH due to the direct effect of progestins on the endometrium, leading to endometrial growth. This stimulatory effect is exacerbated by exposition to oestrogens. Although prescribed, contraception using progestins should be avoided when levels of oestradiol are high as in proestrus. To reduce the risk of uterine illness, treatment should be done during deep anestrus when endogenous levels of oestradiol are low (Evans & Sutton, 1989; Jöchle, 1991) .
The duration of oestrous suppression varies from 4 to 6 months (1-7 months). Posology and duration of treatment are depending on the progestin used and can be reviewed in Romagnoli and Concannon (2003) and Max et al. (2014) .
| Androgens
Testosterone and mibolerone (a derivate of testosterone) are potentially capable to prevent oestrus. Due to the anabolic steroid characteristics of both products, they are controlled or not available in most countries. Mibolerone is a liquid oral formulation, known as "cheque drops" in the USA, and is available as a compounding drug in Australia and New Zealand. Treatment with mibolerone is based on the weight of the bitch (Concannon & Meyers-Wallen, 1991) , at the dose of 16 μg/kg orally, once per day and needs to be started at least 30 days before the next anticipated heat to prevent the oestrus (Root Kustritz, 2012) . It should be used no longer than 24 months.
The mechanism of action is primarily a negative feedback on the hypothalamus and possibly the pituitary gland by testosterone as observed in the normal reproduction of the male dog, where once the gonadal hormones reach a certain concentration via negative feedback it downregulates further release of GnRH, and thus FSH and LH (Linde-Forsberg, 2001 ).
The advantages of testosterone compounds are the lack of effect on the uterus and ovaries as described for progestins. However, some levels of masculinization can be observed such as increase in the muscle mass and strength, hyperplasia of the clitoris, and behavioural changes such as increased aggression and change in vocalization. Furthermore, a viscous mucous vaginal discharge and epiphora have been observed (Concannon & Meyers-Wallen, 1991; Olson et al., 1986; Root Kustritz, 2012) . Since the metabolism of steroids is done by the liver, females with liver problems and/or with predisposition to liver problems should not be treated with mibolerone. Liver function should be checked during treatment. The use of androgens in specific breeds with predisposition to chronic hepatitis as Bedlington terriers (Root Kustritz, 2012) is highly contraindicated.
The return to oestrus after withdrawal of the product is not predictable and can take 1-7 months with an average of 70 days (Olson et al., 1986) .
General and important considerations
Neither progestins nor androgens should be used in prepubertal bitches. In case of inadvertent use in pregnant animals, both can cause masculinization of female foetuses and progestins can also increase the risk of dystocia since the cervix might fail to open due to its progesterone effect.
| Deslorelin implants
Deslorelin implants are not approved to prevent oestrus in the bitch. These implants are labelled for temporary induction of infertility of the male adult dog and to treat hyperadrenocorticism in ferrets. Nevertheless, agonists of the gonadotropin-releasing hormone (GnRH) are supposed to be a good option for suppressing the oestrous cycle and have been used in clinical trials Maenhoudt, Santos, & Fontbonne, 2014; Romagnoli et al., 2009; Trigg et al., 2001 ). The deslorelin implants (4.7 or 9.4 mg) are designed as a biocompatible lipid matrix (saturated triglyceride) that provides a sustained, gradual and steady release. As a GnRH agonist, deslorelin acts at the level of the hypothalamus. The inhibitory effect results from the constant release of deslorelin from the implant leading to downregulation of pituitary GnRH receptors via inhibition of RNA messengers (mRNA) coding for the β-subunits of gonadotropins (Navarro & Schober, 2012) .
After application of the implant, deslorelin has a stimulatory effect on the gonadotropin secretion, known as flare-up effect, resulting in oestrous induction in almost 100% of adult bitches. However, once the downregulation is reached, the plasma concentrations of FSH and LH decrease to basal levels.
Implantation should be done during anestrus, as the flare-up effect occurs even in bitches with high levels of progesterone, as observed during the luteal phase (Fontaine & Fontbonne, 2010) . The oestrous induction during high peripheral levels of progesterone could lead to hormonal imbalance, considered to be a predisposing factor for CEH/pyometra complex (Noakes, Dhaliwal, & England, 2000) .
The duration of oestrous prevention after a single downregulation by deslorelin has a considerable variation from 2 to 27 months regardless of the dose of the implant (Maenhoudt et al., 2014; Trigg et al., 2001) . Repeated applications of 4.7-or 9.4-mg deslorelin implants led to anestrus for 4 years (Romagnoli et al., 2009) . This variation should be considered before using the deslorelin implant in breeding bitches at an older age (>5 year old) since by the time the return to oestrus is observed, after 6 years of age, pregnancy rate and litter size decrease and neonatal losses increase even when all other factors remain constant (Johnson, 2008) . Side effects are rarely described, but they can be important in nature. Persistent oestrus, ovarian cysts, lactation and behavioural changes have been reported. In the majority of the publications, removal of the subcutaneous (post-umbilical area or medial side of the hind leg) implant resolved the problem within 15 days. Nevertheless, ovariectomy was also described as a solution for the side effect, which limits the use in breeding animals (Fontaine & Fontbonne, 2010) . In a retrospective study by Palm and Reichler (2010) , postimplantation metropathies were observed in bitches with or without clinical signs of oestrus. Advanced age or a history of previous progestin treatment was a predisposing factor. In these cases, the treatment of choice was ovariohysterectomy. Furthermore, a case was reported regarding the use of deslorelin implant during luteal phase in a 7-year-old female for oestrous suppression. This bitch developed ovarian cysts with subsequent pyometra after injections of hCG (human chorionic gonadotropin), and surgery was necessary (Arlt, Spankowsky, & Heuwieser, 2011) . Therefore, the use of deslorelin must be done under supervision of a veterinarian in order to follow-up the treated animal. The main disadvantage in using deslorelin in adult bitches for oestrous prevention is the initial flare-up effect inducing oestrus as unwanted reaction and may be, most likely, the major reason why deslorelin is still not authorized for oestrous prevention. Even though a number of alternatives have been tried to suppress the flare-up effect, no safe and effective protocol is available so far (Anjolras, 2011; Corrada, Hermo, Johnson, Trigg, & Gobello, 2006; Sung, Armour, & Wright, 2006; Trigg et al., 2001; Valiente et al., 2009; Wright et al., 2001 ).
The advantages of using deslorelin for oestrous prevention are, besides being a reversible method of chemical castration, that side effects are rarely described and fertility after treatment does not seem affected (Borges et al., 2015) if used in well-selected patients.
A positive aspect of deslorelin is that it interferes at the hypothalamus level via GnRH receptors and the FSH/LH secretion loop (Navarro & Schober, 2012) , and by this, has no direct impact on the ovaries and/or the uterus what might minimize negative influences on fertility. Potentially, deslorelin can be used for oestrous prevention in pet-owned dogs where implantation can be performed at the same time as vaccination if the time of the oestrous cycle is suitable.
However, all bitches implanted should be closely monitored for signs of persistent oestrus or uterine diseases. Even though side effects are not common, they should be fully discussed with the owners.
Some of the side effects can have an impact on future fertility and on the general health of the bitch.
| Other options
The ideal method for contraception in dogs, mainly for population control, is still to be found. Attempts have been done to discover a single non-surgical alternative to suppress fertility in female dogs (Rhodes, 2017) . Nicotine has been used successfully to prevent heat However, the lack of information on the impact on future health of the animal and the ethical aspects of the use of nicotine limit its current use as a contraceptive. Methods which should get attention in the near future are gene silencing (Dissen et al., 2012) , manipulation of the Muellerian inhibiting substance (MIS) (Pepin et al., 2016) 
| OE S TROUS INDUC TI ON OP TI ON S , MECHANIS MS OF AC TI ON AND S IDE EFFEC TS
As indicated before, there are different reasons for induction of oestrus in bitches. Considering the clinical aspects, the major reasons are primary anestrus (bitches older than 2 years never having shown signs of heat), secondary anestrus (interoestrous interval of more than 1 year, except for primitive breeds as Basenji) and individual bitches with prolonged interoestrous interval. The onset of a new cycle and the termination of the long obligatory anestrus are not understood in the bitch (Concannon, 2011) . However, neither the pituitary gland nor the ovary has been shown to be completely quiescent during anestrus (Kooistra et al., 1999) , making possible the use of protocols for oestrous induction in the bitch. Progression from early to late anestrus in the bitch is characterized by an increase in GnRH secretion (pulses and frequency) followed by higher levels of sensitivity of the pituitary to GnRH, as indicated by an increasing pulsatility in LH secretion (de Gier, Beijerink, Kooistra, & Okkens, 2008; Okkens & Kooistra, 2006) , and of ovarian responsiveness to gonadotropins (Jeffcoate, 1993; Van Haaften et al., 1994) .
At the moment, oestrous induction in the bitch can be performed using dopamine agonists (anti-prolactinergic drugs like cabergoline and bromocriptine) and GnRH agonists (deslorelin implant).
Pre-requisites for successful oestrous induction are sexual maturity, reproductive health (normal ovarian and uterine function) and the oestrous cycle stage (at least 5 months from the previous oestrus). The longer the interval from the previous oestrus is, the better are the results. Therefore, the prefect candidate should be in progressed to late anestrus (vaginal cytology of anestrus and progesterone levels less than 1 ng/ml) was shown to be effective as well (Ajitkumar, Praseeda, Rajankutty, & Alex, 2010; Cirit et al., 2007) . The duration of treatment varies from 8 to 40 days, and the efficacy of oestrous induction is highly associated with the stage of anestrus when the treatment is started (Van Haaften et al., 1989; Verstegen, Onclin, Silva, & Concannon, 1999) . In late anestrus, a shorter treatment period is required. The percentage of bitches that do not respond to the treatment and the maximum time of treatment before it is considered ineffective has not been sufficiently evaluated (Romagnoli & Lopate, 2017) . As shown for the efficacy regarding oestrous induction, the pregnancy rate is influenced by the stage of anestrus, in which the treatment is performed with better results if treatment takes place in late anestrus. Pregnancy rates of 70% to 100% have been obtained after oestrous induction using dopamine agonists (Ajitkumar et al., 2010; Cirit et al., 2007; Gobello, Castex, & Corrada, 2002; Günay, Günay, & Soylu, 2004; Shimatsu, 2017; Verstegen et al., 1999; Zöldág, Fekete, Csáky, & Bersényi, 2001) . In a recent study, the administration of Oestrous induction with dopamine agonists might not be necessarily associated with a decline in prolactin but seems to exert a direct GnRH-stimulating effect on the hypothalamic level (Okkens & Kooistra, 2006) . Although the suppression of prolactin seems to be a key player for the action of the dopamine, it is obviously not essential since proestrus was induced in bitches without lowering the plasma prolactin concentration (Beijerink, Dieleman, Kooistra, & Okkens, 2003) .
| Dopamine agonists
Side effects are occasionally observed during the treatment with dopamine agonists. Bromocriptine has been shown to cause vomiting (Van Haaften et al., 1989) , whereas cabergoline led to changes in the coat colour from the second week of administration to the next coat shedding when treatment was done for more than 14 days (Gobello, Castex, Broglia, & Corrada, 2003) . Although it has not been described in female dogs, oral treatment with cabergoline for 28 days seems to induce a hypothyroid condition in castrated male dogs (Günzel-Apel et al., 2009).
| Deslorelin implant
Similar to dopamine agonists, deslorelin implants should be used during anestrus. At present, deslorelin is the only GnRH agonist available for use in veterinary medicine. One is the Ovuplant® containing 2.1 mg deslorelin (Dechra, UK) and authorized for horses, and the other is Suprelorin® containing 4.7 or 9.4 mg deslorelin (Virbac, France) authorized for male dogs and ferrets. As described above (see Deslorelin implants), the primary effect of a deslorelin implant is an increase in FSH and LH known as the "flare up" effect, leading to oestrous induction in >90% of the treated bitches. This occurs irrespective of the stage of anestrus (early, mid or late) (Fontaine & Fontbonne, 2010; Fontaine, Mir, Vannier, Gerardin, Albouy, Navarro et al., 2011; Kutzler, 2002; .
Clinical signs of proestrus are presented within 1 week after implantation (Fontaine, Mir, Vannier, Gerardin, Albouy, Navarro et al., 2011; von Heimendahl & Miller, 2012; 2009; Maenhoudt C., Thoumire S., Fontaine, & Fontbonne, 2016; Walter, Otzdorff, Brugger, & Braun, 2011) . Since signs of heat can be discrete in individual bitches, careful controls should start 1 week after implantation. Once the bitch is in heat, the follow-up is similar as in spontaneous oestrus with evaluation of progesterone to determine ovulation and breeding time. In the majority of the cases, ovulation occurs around 12 days (8-16 days) after implantation (Fontaine, Mir, Vannier, Gerardin, Albouy, Navarro et al., 2011; von Heimendahl & Miller, 2012; Maenhoudt C. et al., 2016; Walter et al., 2011) . Overall ovulation rates in deslorelin induced oestrus are variable and above 75% (Borges et al., 2015; Fontaine, Mir, Vannier, Gerardin, Albouy, Navarro et al., 2011; von Heimendahl & Miller, 2012; Maenhoudt C. et al., 2016; Walter et al., 2011) . No difference was observed in the ovulation rate in bitches after single or multiple oestrous induction with deslorelin (Borges et al., 2015) . Reasons for an anovulatory oestrus are not fully understood. One possible reason may be the deficit in gonadotropin secretion, especially in the pre-ovulatory LH surge needed for induction of ovulation (Fontaine, Mir, Vannier, Gerardin, Albouy, Navarro et al., 2011) . Anovulatory cycles were observed in 38.5% of bitches treated in early anestrus (80-160 days after previous oestrus) in comparison with 13.5% in late anestrus (200-590 days from the previous oestrus) (Fontaine, Mir, Vannier, Gerardin, Albouy, Navarro et al., 2011) . According to the differences in pituitary responsiveness to GnRH during the course of anestrus, as intensively described above (see Deslorelin implants), the low sensitivity of the pituitary gland in early anestrus (Van Haaften et al., 1994) appears to be a comprehensible cause.
Pregnancy rates obtained after mating in deslorelin induced heats are also variable (Borges et al., 2015; Fontaine, Mir, Vannier, Gerardin, Albouy, Navarro et al., 2011; von Heimendahl & Miller, 2012; Maenhoudt C. et al., 2016; Walter et al., 2011) , with an overall rate of 60%.
This relatively low pregnancy rate is a reflection of different factors.
Despite all aspects that could interfere with reproduction success like age, parity, uterine health, breeding management (natural breeding or insemination), semen quality and fertility of the male dog, the individual sensitivity to the GnRH agonist treatment (Concannon, Temple, Montanez, & Newton, 2006) and the stage of anestrus at the time of implantation must be considered. One factor of great importance seems to be the minimal duration of the interoestrous interval (at least 135 days) to allow the uterus to undergo a proper rest as suggested by .
The effect of oestrous induction with deslorelin on litter size has been analysed in only two studies so far. Litter size did not differ among females of different breeds in relation to natural or induced oestrus with Suprelorin ® (Borges et al., 2015) . However, when using Ovuplant ® for oestrous induction in German Shorthair Pointer bitches, the number of puppies was reduced in relation to spontaneous oestrus (Wolf, Meyer, & Kutzler, 2012) . The difference in concentration of the two implants has not been addressed.
Removing the implant is needed in all bitches implanted for oestrous induction. According to our clinical experience, we recommend to remove the implant after ovulation has been detected as indicated by a representative progesterone level (Fontaine, Mir, Vannier, Gerardin, Albouy, Navarro et al., 2011; von Heimendahl & Miller, 2012; Maenhoudt C. et al., 2016; Wolf et al., 2012) or 2-3 weeks after implantation in case of ovulation failure. Therefore, the implant should be placed subcutaneously in an area of easy access. The postumbilical area (Borges et al., 2015; Fontaine, Mir, Vannier, Gerardin, Albouy, Navarro et al., 2011; von Heimendahl & Miller, 2012; Maenhoudt C. et al., 2016) or the internal side of the posterior leg (Walter et al., 2011) has been used with similar results. Implantation in the vestibular mucosa (Kutzler et al., 2009 ) is not necessary and not recommended.
If the implant is not removed in time, pregnant bitches are at risk of luteal insufficiency (Fontaine, Mir, Vannier, Gerardin, Albouy, Navarro et al., 2011; Kutzler et al., 2009; Maenhoudt C. et al., 2016; Volkmann, Kutzler, Wheeler, & Krekeler, Klewitz, 2006) and nonpregnant bitches can undergo prolong suppression of the oestrous cycle, as discussed above (see Deslorelin implants). Luteal failure is most likely due to suppression of the LH secretion when function of the corpora lutea is still dependent on support from the pituitary gland (Okkens, Dieleman, Bevers, Lubberink, & Willemse, 1986) .
Moreover, even after implant removal, luteal failure has been suspected (Fontaine, Mir, Vannier, Gerardin, Albouy, Navarro et al., 2011) . Therefore, progesterone levels should be evaluated during the whole pregnancy in order to monitor luteal function.
Efficacy and risks of the treatment with a deslorelin implant should be intensively discussed with the clients. In general, even though almost 100% of the bitches will display oestrous signs after receiving the deslorelin implant, considering an ovulation rate of 80% and a pregnancy rate of 70%, the likelihood for the bitch to become pregnant is around 50%. Fertility seems to be reduced when ovulation occurs later than 13 days after implantation (Fontaine, Mir, Vannier, Gerardin, Albouy, Navarro et al., 2011) .
General considerations
Today, there are two oestrous induction protocols with sufficient data to guarantee the use in bitches with very little contraindications. To our knowledge, no clinical research compared the rate of oestrous induction and pregnancy rates between dopamine agonists and deslorelin. The success rate seems to be slightly different. For cabergoline, if the bitches come in heat, the vast majority will ovulate and develop a stable luteal phase, but not all bitches will come into heat. On the other hand, almost 100% of the bitches will show heat (signs more or less pronounced) after deslorelin implantation, but not all will ovulate. The impact of the stage of anestrus at the time of treatment on the success rate is similar for both methods. It increases with the duration of the interoestrous interval and anestrus, respectively. It is important to emphasize towards clients that heat induction in bitches showing oestrus regularly every 5-6 months has very little gain and an increased risk of reducing fertility. Before any attempt to induce oestrus, it is necessary to confirm that the bitch is in anestrus (interval to last previous heat, vaginal cytology and progesterone assay) and to perform an ultrasound examination to evaluate ovaries and uterus.
In case of a pathological ovarian and/or uterine condition, oestrous induction is contraindicated.
| CON CLUS ION
Management of the oestrous cycle in dogs has become a common request of clients to prevent or optimize breeding in bitches.
Although the ideal method for oestrous prevention for population control is not available, there are different options for pet-owned dogs. The decision regarding a certain treatment must be made case by case considering the individual conditions.
For oestrous induction, deslorelin seems to be the primary choice in clinics due to the shorter period from treatment to heat observation but a careful selection of the patient and side effects should be considered. Nevertheless, cabergoline has shown good results with less side effects. Knowing all the existing options gives the prospect to make the best choice for each case. Fertility after multiple attempts to induce oestrus by using cabergoline or deslorelin has not been fully addressed. In a retrospective study with nine bitches submitted to deslorelin treatment for oestrous induction (4.7 mg, two times-n = 7, ≥ three times-n = 3), the pregnancy rate was 90% (Borges et al., 2015) . However, further studies are needed to evaluate the fertility and prolificity in case of multiple attempts of oestrous induction using cabergoline or deslorelin.
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